Regeneron Incorporated reported compelling early clinical data demonstrating 100% response rate in a small study of its T cell engager drug Lynozyfic in patients with smoldering multiple myeloma, a precursor to active multiple myeloma. These results support further development and potential expansion of Lynozyfic for earlier disease stages, offering promise to patients at risk of disease progression. Such data mark a significant step in Regeneron’s oncology portfolio advancement.